fCAL® turbo RECEIVES 510(K) CLEARANCE IN THE USA

28. Jun 2019 | 3 min read

Moss, 28.06.2019
Gentian Diagnostics AS is pleased to announce that BÜHLMANN has received 510(k) clearance (K190784) from the FDA for the BÜHLMANN fCAL® turbo. BÜHLMANN is Gentian’s exclusive commercial partner for the fecal calprotectin products worldwide.

 

The potential US fecal calprotectin market is of an estimated size of USD ~30 million, while the current market is of an estimated size of USD ~5 million. Hilja Ibert, CEO Gentian Diagnostics AS comments “While the fecal calprotectin market size in the US is still quite small, fecal calprotectin is part of a high annual growth market, as observed in Europe. The already FDA cleared BÜHLMANN fCAL® ELISA has paved the way for BÜHLMANN fCAL® turbo which will allow for high throughput analysis of fecal calprotectin in applicable core laboratories and screening programmes.”

 

For further information, please contact:
 
Hilja Ibert CEO
Gentian Diagnostics AS
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

 

Njaal Kind CFO,
Gentian Diagnostics AS
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525
 
MeldingsID: 480471

 

 
 

You may also read


Dec 16, 2019 - Kristin Hart

Financial calendar

Financial calendar for Gentian Diagnostics AS

Dec 05, 2019 - Kristin Hart

Gentian Diagnostics presents at DNB conference in New York

Moss 05.12.19 The CEO of Gentian Diagnostics, Dr. Hilja Ibert, will today give a company presentation at the..

Nov 29, 2019 - Kristin Hart

Share capital increase registered

Reference is made to the stock exchange notice from Gentian Diagnostics AS (the "Company") on 25 November..